SEC Form 4 · accession 0001209191-16-151477
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey S Glenn
Director
Period of report
Nov 17, 2016
Accepted (ET)
Nov 21, 2016 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 17, 2016 | P | 15,000 | $12.73 | A | 16,355 | D | |
| Common Stock | Nov 18, 2016 | P | 460 | $12.90 | A | 460 | I | By son |
| Common StockF1 | holding | — | — | — | 151,064 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares are held by Eiger Group International, Inc. ("EGI"). The Reporting Person is the Chief Executive Officer of EGI and has sole power to vote and sole power to dispose of shares directly owned by EGI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.